REPLIGEN CORP Tax Withholding Paid on Stock Awards
REPLIGEN CORP (RGEN) reported Tax Withholding Paid on Stock Awards of $6.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-07-29
- REPLIGEN CORP payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $1.07M, a 58.14% increase year-over-year.
- REPLIGEN CORP payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $5.54M, a 14.64% decline year-over-year.
- REPLIGEN CORP payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $839.00K, a 75.16% increase year-over-year.
- REPLIGEN CORP payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $824.00K, a 50.92% increase year-over-year.
- REPLIGEN CORP payment, tax withholding, share-based payment arrangement for fiscal 2025 was $8.83M, a 10.62% decline from fiscal 2024.
- REPLIGEN CORP payment, tax withholding, share-based payment arrangement for fiscal 2024 was $9.88M, a 25.29% decline from fiscal 2023.
- REPLIGEN CORP payment, tax withholding, share-based payment arrangement for fiscal 2023 was $13.23M, a 22.28% decline from fiscal 2022.
- REPLIGEN CORP payment, tax withholding, share-based payment arrangement for fiscal 2022 was $17.02M, a 487.44% increase from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $6.61M 10-Q · filed 2026-07-29 | $7.45M derived: sum of 3 quarters · filed 2026-07-29 | $8.28M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $5.54M 10-Q · filed 2026-05-06 | $6.38M derived: sum of 2 quarters · filed 2026-05-06 | $7.21M derived: sum of 3 quarters · filed 2026-05-06 | $7.88M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.66M derived: sum of 2 quarters · filed 2026-02-26 | $2.34M derived: sum of 3 quarters · filed 2026-07-29 | $8.83M 10-K · filed 2026-02-26 |
| 2025-09-30 | $824.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.50M derived: sum of 2 quarters · filed 2026-07-29 | $7.99M 10-Q · filed 2025-11-04 | $8.47M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $676.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $7.17M 10-Q · filed 2026-07-29 | $7.65M derived: sum of 3 quarters · filed 2026-07-29 | $8.20M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $6.49M 10-Q · filed 2026-05-06 | $6.97M derived: sum of 2 quarters · filed 2026-05-06 | $7.52M derived: sum of 3 quarters · filed 2026-05-06 | $8.75M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $479.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.02M derived: sum of 2 quarters · filed 2026-02-26 | $2.26M derived: sum of 3 quarters · filed 2026-02-26 | $9.88M 10-K · filed 2026-02-26 |
| 2024-09-30 | $546.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.78M derived: sum of 2 quarters · filed 2025-11-04 | $9.40M 10-Q · filed 2025-11-04 | $10.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $8.86M 10-Q · filed 2025-08-07 | $9.91M derived: sum of 3 quarters · filed 2026-02-26 | $10.94M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $7.62M 10-Q · filed 2025-04-29 | $8.67M derived: sum of 2 quarters · filed 2026-02-26 | $9.71M derived: sum of 3 quarters · filed 2026-02-26 | $11.26M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.05M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $2.09M derived: sum of 2 quarters · filed 2026-02-26 | $3.63M derived: sum of 3 quarters · filed 2026-02-26 | $13.23M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.04M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $2.59M derived: sum of 2 quarters · filed 2024-11-18 | $12.18M 10-Q/A · filed 2024-11-18 | $13.37M derived: sum of 4 quarters · filed 2025-03-14 |
| 2023-06-30 | $1.55M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $11.14M 10-Q/A · filed 2024-11-18 | $12.33M derived: sum of 3 quarters · filed 2025-03-14 | $13.40M derived: sum of 4 quarters · filed 2025-03-14 |
| 2023-03-31 | $9.59M 10-Q/A · filed 2024-11-18 | $10.78M derived: sum of 2 quarters · filed 2025-03-14 | $11.85M derived: sum of 3 quarters · filed 2025-03-14 | $14.30M derived: sum of 4 quarters · filed 2025-03-14 |
| 2022-12-31 | $1.19M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $2.26M derived: sum of 2 quarters · filed 2025-03-14 | $4.71M derived: sum of 3 quarters · filed 2025-03-14 | $17.02M 10-K · filed 2025-03-14 |
| 2022-09-30 | $1.07M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $3.52M derived: sum of 2 quarters · filed 2024-11-18 | $15.83M 10-Q/A · filed 2024-11-18 | $17.47M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | $2.45M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $14.76M 10-Q/A · filed 2024-11-18 | $16.40M derived: sum of 3 quarters · filed 2024-11-18 | $17.66M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | $12.31M 10-Q/A · filed 2024-11-18 | $13.96M derived: sum of 2 quarters · filed 2024-11-18 | $15.21M derived: sum of 3 quarters · filed 2024-11-18 | |
| 2021-12-31 | $1.65M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $2.90M derived: sum of 2 quarters · filed 2024-11-18 | $2.90M 10-K/A · filed 2024-11-18 | |
| 2021-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $1.25M 10-Q · filed 2022-11-01 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-02 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 derived: sum of 3 quarters · filed 2023-02-22 | $10.00K 10-K · filed 2023-02-22 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $0.00 derived: sum of 2 quarters · filed 2021-10-28 | $10.00K 10-Q · filed 2021-10-28 | $210.00K derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27 | $10.00K 10-Q · filed 2021-07-27 | $210.00K derived: sum of 3 quarters · filed 2022-02-17 | |
| 2020-03-31 | $10.00K 10-Q · filed 2021-05-04 | $210.00K derived: sum of 2 quarters · filed 2022-02-17 | ||
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $490.00K 10-K · filed 2022-02-17 | ||
| 2019-09-30 | $290.00K 10-Q · filed 2020-11-05 | |||
| 2017-12-31 | $1.72M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |